Lancet Neurol: Cerebrospinal fluid and blood biomarkers for the diagnosis of Alzheimer's disease
Release date: 2016-04-15 Biomarkers of Alzheimer's disease (AD) are important for early clinical diagnosis and research. A number of studies have evaluated three major cerebrospinal fluid biomarkers (Aβ42, T-tau, and P-tau) for the diagnosis of AD, and some other biomarkers have emerged in the literature. However, there is no comprehensive meta-analysis of the diagnostic performance of these biomarkers. We systematically returned to the 15 biomarkers in the cerebrospinal fluid and blood of the literature to assess some of the most variable markers in AD. We reviewed the reactive neurodegeneration (T-tau, NFL, NSE, VLP-1, and HFABP), APP metabolism (Aβ42, Aβ40) on PubMed and Science Network from January 1, 1984 to June 30, 2014. , Aβ38, sAPPα, andsAPPβ), neurofibrillary tangles (P-tau), blood-brain barrier function (protein ratio), astrocyte activation (YKL-40, MCP-1, GFAP) cerebrospinal fluid and blood organisms landmark. Data source cross-sectional studies and baseline measurements of longitudinal studies with clinical follow-up. Experiments that did not include the AD cohort and control group were excluded, and there was no cohort of mild cognitive dysfunction and stable mild cognitive dysfunction due to AD. Data was extracted by 10 authors and 2 authors checked to ensure accuracy. The adjusted QUADAS standard was used to assess the quality of the experimental data. The performance of biomarkers is measured by the ratio of biomarker concentrations (fold changes) in AD patients and controls, or mild cognitive dysfunction caused by AD and those with stable cognitive dysfunction for at least 2 years of follow-up The ratio of further decline in cognitive function did not appear to be measured. In the PubMed, 4521 records were identified, the scientific website identified 624 records, and 231 articles in the analysis included 15699 AD patients and 13018 control subjects. The main biomarkers that performed well to distinguish between Alzheimer's disease and the control group were CSFT-tau (mean ratio 2.54, 95% CI 2·44–2·64, p<0·0001), P-tau (1·88, 1.79–1·97, p<0·0001), and Aβ42 (0·56, 0·55–0·58, p<0·0001). The differences between mild cognitive dysfunction caused by AD and patients with stable cognitive dysfunction are also large (mean ratio CSF0·67Aβ42, P-tau 1·72fo, T-tau 1.76). In addition, CSF NFL (2·35, 1.90–2·91, p<0·0001) and serum T-tau (1·95, 1·12–3·38, p=0·02) There was a large effect in distinguishing AD from the control group, and CSF NSE, VLP-1, HFABP, and YKL-40 had moderate effects (mean ratio 1.28–1·47). Other biomarkers evaluated had only a small effect or no difference in the control and patient samples at all. Major biomarkers of neurodegenerative changes (T-tau, P-tau, and Aβ42), CSF NFL, and serum T-tau are strongly associated with Alzheimer's disease and are caused by Alzheimer's disease. Mild cognitive dysfunction has a strong relationship. Emerging cerebrospinal fluid biomarkers NSE, VLP-1, HFABP, and YKL-40 are moderately associated with Alzheimer's disease, and serum Aβ42 and Aβ40 are not associated with AD. Due to their stability, T-tau, P-tau, Aβ42, and NFL in cerebrospinal fluid should be recommended for clinical practice and clinical research in Alzheimer's disease. Original source: Dr Bob Olsson, Ronald Lautner, MD, Ulf Andreasson, et al, CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, lancet neurology, Published Online: 08 April 2016 Source: Metz Medicine Greenhouse Plastic Plastic Clamps Greenhouse Plastic Plastic Clamps,Greenhouse Structure Connecting Clamps,Agricultural Greenhouses Clamps,Plastic Clamps JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.skyplantgreenhouse.com